Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 14 Issue 3, March 2008

In this issue (p 331), Ru-Rong Ji and colleagues report that different matrix metalloproteinase family members play distinct roles in the initiation and maintenance of neuropathic pain. Image of a dorsal root ganglion courtesy of Ru-Rong Ji.

Editorial

  • An Institute of Medicine report recommends that the United States government create a program to provide consistent guidelines for clinical interventions. The reliability of the guidelines will depend on the availability of the clinical data to be assessed.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Correspondence

Top of page ⤴

Book Review

Top of page ⤴

News & Views

  • Matrix metalloproteases (MMPs) are shedding their traditional roles in tissue remodeling and appearing as players in diseases of the nervous system. MMP2 and MMP9 provide the latest example, with converging roles in chronic pain after peripheral nerve injury (pages 331–336).

    • Simon Beggs
    • Michael W Salter
    News & Views
  • A well-known cell cycle regulator, p27KIP1, and protein kinase CK2-α´ mediate pathologic growth of cardiomyocytes. The findings have potential implications for the development of new treatment approaches to cardiac hypertrophy (pages 315–324).

    • Thomas Force
    News & Views
  • Inhibition of the Notch pathway reverses damage in a mouse model of kidney disease (pages 290–298). The findings suggest that blockade of the Notch pathway through inhibition of γ-secretase activity may be an approach to combating glomerular failure.

    • Matthias Kretzler
    • Lisa Allred
    News & Views
  • Interleukin-22, a component of the immune system most studied for its role in autoimmunity, has a more beneficial side. Two studies show how this cytokine fights off microbes in the mucosa of the lung and gut (pages 275–281 and 282–289).

    • Arian Laurence
    • John J O'Shea
    • Wendy T Watford
    News & Views
  • A recent theory about the basis for fragile X syndrome is now validated in a mouse model. The findings point the way to treatment options targeting group 1 metabotropic glutamate receptors.

    • Gary J Bassell
    • Christina Gross
    News & Views
Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Technical Report

Top of page ⤴

Corrigendum

Top of page ⤴

Search

Quick links